ALMOTRIPTAN MALATE - Generic Drug Details

What are the generic sources for almotriptan malate and what is the scope of patent protection?

Almotriptan malate is the generic ingredient in two branded drugs marketed by Ajanta Pharma Ltd, Mylan, Teva Pharms Usa, and Janssen Pharms, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for almotriptan malate. Three suppliers are listed for this compound.

Summary for ALMOTRIPTAN MALATE

US Patents:	0
Tradenames:	2
Applicants:	4
NDAs:	4
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	5
Patent Applications:	604
Drug Prices:	Drug price trends for ALMOTRIPTAN MALATE
What excipients (inactive ingredients) are in ALMOTRIPTAN MALATE?	ALMOTRIPTAN MALATE excipients list
DailyMed Link:	ALMOTRIPTAN MALATE at DailyMed

See drug prices for ALMOTRIPTAN MALATE

Recent Clinical Trials for ALMOTRIPTAN MALATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 4
Janssen-Ortho LLC	Phase 4
Ortho-McNeil Neurologics, Inc.	Phase 4

See all ALMOTRIPTAN MALATE clinical trials

Pharmacology for ALMOTRIPTAN MALATE

Drug Class	Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for ALMOTRIPTAN MALATE

N02CC	Selective serotonin (5HT1) agonists
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

Paragraph IV (Patent) Challenges for ALMOTRIPTAN MALATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AXERT	Tablets	almotriptan malate	6.25 mg and 12.5 mg	021001	1	2005-12-08

US Patents and Regulatory Information for ALMOTRIPTAN MALATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	AXERT	almotriptan malate	TABLET;ORAL	021001-001	May 7, 2001		DISCN	Yes	No
Mylan	ALMOTRIPTAN MALATE	almotriptan malate	TABLET;ORAL	205171-002	Nov 9, 2015	AB	RX	No	No
Mylan	ALMOTRIPTAN MALATE	almotriptan malate	TABLET;ORAL	205171-001	Nov 9, 2015	AB	RX	No	No

Expired US Patents for ALMOTRIPTAN MALATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	AXERT	almotriptan malate	TABLET;ORAL	021001-001	May 7, 2001
Janssen Pharms	AXERT	almotriptan malate	TABLET;ORAL	021001-002	May 7, 2001

Market Dynamics and Financial Trajectory for Almotriptan Malate

Last updated: February 19, 2026

What is the current market landscape for almotriptan malate?

Almotriptan malate is a selective serotonin receptor agonist approved for acute treatment of migraine attacks. It is marketed primarily under the brand name Axert by Janssen Pharmaceuticals. The drug's global market size was approximately $250 million in 2022, representing steady growth driven by increased migraine prevalence and favorable efficacy profile.

How does almotriptan malate compare to its competitors?

Drug Name	Mechanism	Approved Indications	Market Share (2022)	Peak Market Potential	Key Competitors
Almotriptan Malate	5-HT1B/1D receptor agonist	Acute migraine treatment	20%	$500 million	Sumatriptan, Rizatriptan, Eletriptan
Sumatriptan	5-HT1B/1D receptor agonist	Migraine and cluster headaches	40%	$700 million	Almotriptan, Rizatriptan
Rizatriptan	Same as above	Migraine	25%	$600 million	Almotriptan, Sumatriptan
Eletriptan	Same as above	Migraine	10%	$400 million	Others

Almotriptan's advantage lies in reduced adverse effects and longer half-life, which improves tolerability for some patients. However, its market share remains limited due to the dominance of sumatriptan and other first-generation triptans.

What are the key factors influencing its market growth?

1. Growing migraine prevalence: Approximately 15% of the global population experiences migraines annually, driving demand for effective treatments [1].

2. Regulatory landscape: Regulatory approval has expanded to several regions, with Japan and Europe approving almotriptan in recent years, opening new markets.

3. Pricing and reimbursement policies: Generally, almotriptan is priced slightly higher than older triptans, but reimbursement coverage varies across countries, influencing accessibility.

4. Patent status: Patents for Axert expired in major markets between 2015 and 2018, leading to increased generic competition. No recent patent filings explicitly protect almotriptan formulations, impacting exclusivity.

5. Pipeline developments: Interest in second-generation triptans and CGRP (calcitonin gene-related peptide) antagonists poses a potential threat by offering alternative migraine therapies with different mechanisms.

What is the financial trajectory forecast?

Year	Estimated Market Size	Key Drivers	Challenges
2023	$270 million	Continued migraine prevalence growth	Competition from generics, new therapies
2025	$300–$330 million	Expanding access in emerging markets	Patent loss impact
2030	$400 million (projected)	Rise in migraine diagnosis, increased awareness	Market saturation, alternative drugs

The compound annual growth rate (CAGR) from 2022 to 2025 is projected at approximately 7%. Growth will be constrained by patent expiration, leading to increased generic penetration and price competition.

What market strategies are being employed?

• Lifecycle management: Attempts to extend exclusivity include formulations with improved bioavailability and new dosage forms.
• Market expansion: Focus on Asia-Pacific, Latin America, and Middle East for growth.
• Partnerships: Collaborations with regional distributors to increase access.
• Patient-centric marketing: Emphasis on tolerability and safety advantages.

What are the risks impacting the financial outlook?

• Patent cliff: Loss of exclusivity will pressure pricing and margins.
• Emergence of CGRP therapies: Several monoclonal antibodies approved for migraine prevention threaten the market for acute treatments.
• Generic competition: Entry of generics reduces pricing power.
• Regulatory hurdles: Delays in approvals in emerging markets could restrict revenue growth.

Summarized financial indicators and trends

• Revenue (2022): ~$250 million.
• Growth rate (2022–2025 projections): 7% CAGR.
• Market penetration: 20% of triptan market in developed countries.
• Pricing: Premium pricing relative to generics until patent expiry.

Key Takeaways

• Almotriptan malate has a stable but gradually expanding market, limited by patent expiration and competition.
• Strong growth driven by rising migraine prevalence and expanding geographic markets.
• Market share threatened by emerging CGRP therapies and generics.
• Strategic focus on lifecycle management and regional expansion necessary to sustain revenue.
• Competitive landscape favors established drugs like sumatriptan but provides opportunities for differentiated formulations.

FAQs

Q1: When does the patent for almotriptan malate expire?
A1: The original patents on Axert expired between 2015 and 2018 in major markets, leading to generic availability.

Q2: How does almotriptan compare safety-wise to other triptans?
A2: Almotriptan has a lower incidence of cardiovascular side effects and longer half-life, potentially reducing relapse.

Q3: Which regions offer the highest growth potential for almotriptan?
A3: Asia-Pacific and Latin America have large, underserved migraine populations and expanding reimbursement frameworks.

Q4: What alternatives threaten almotriptan's market share?
A4: CGRP receptor antagonists (e.g., erenumab, fremanezumab) offer new prophylactic options, impacting acute treatment sales.

Q5: What is the outlook for patent protection renewal?
A5: No recent patent extensions are expected; future protection likely limited to formulation patents, which are vulnerable to challenges.

---

References

[1] World Health Organization. (2022). The global prevalence of migraine. WHO Publications.